A prospective open trial of guanfacine in children with pervasive developmental disorders

Lawrence Scahill, Michael G. Aman, Christopher J. McDougle, James T. McCracken, Elaine Tierney, James Dziura, L. Eugene Arnold, David Posey, Christopher Young, Bhavik Shah, Jaswinder Ghuman, Louise Ritz, Benedetto Vitiello, Yaser Ramadan, Andrea Witwer, Ronald Lindsay, Naomi Swiezy, Arlene Kohn, Pegeen Cronin, James McGoughLisa Sea Yun Lee, Andres Martin, Kathleen Koenig, Deirdre Carroll, Allison Lancor, Nilda M. Gonzalez, Marco Grados, Shirley Chuang, Mark Davies, James Robinson, Don McMahon

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Objective: A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity. The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in children with FDD and hyperactivity. Methods: Children with PDD accompanied by hyperactivity entered the open-label trial if there was a recent history of failed treatment with methylphenidate or the child did not improve on methylphenidate in a multisite, placebo-controlled trial. Results: Children (23 boys and 2 girls) with a mean age of 9.03 (±3.14) years entered the open-label trial. After 8 weeks of treatment, the parent-rated Hyperactivity subscale of the Aberrant Behavior Checklist (ABC) went from a mean of 31.3 (±8.89) at baseline to 18.9 (±10.37) (effect size = 1.4; p < 0.001). The teacher-rated Hyperactivity subscale decreased from a mean of 29.9 (±9.12) at baseline to 22.3 (±9.44)-(effect size = 0.83; p < 0.01). Twelve children (48%) were rated as Much Improved or Very Much Improved on the Clinical Global Impressions-Improvement. Doses ranged from 1.0 to 3.0 mg/day in two or three divided doses. Common adverse effects included irritability, sedation, sleep disturbance (insomnia or midsleep awakening), and constipation. Irritability led to discontinuation in 3 subjects. There were no significant changes in pulse, blood pressure, or electrocardiogram. Conclusions: Guanfacine may be useful for the treatment of hyperactivity in children with PDD. Placebo-controlled studies are needed to guide clinical practice.

Original languageEnglish
Pages (from-to)589-598
Number of pages10
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number5
DOIs
StatePublished - Oct 2006

Fingerprint

Guanfacine
Methylphenidate
Placebos
Blood Pressure
Sleep Initiation and Maintenance Disorders
Constipation
Checklist
Sleep
Electrocardiography
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Dziura, J., ... McMahon, D. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589-598. https://doi.org/10.1089/cap.2006.16.589

A prospective open trial of guanfacine in children with pervasive developmental disorders. / Scahill, Lawrence; Aman, Michael G.; McDougle, Christopher J.; McCracken, James T.; Tierney, Elaine; Dziura, James; Arnold, L. Eugene; Posey, David; Young, Christopher; Shah, Bhavik; Ghuman, Jaswinder; Ritz, Louise; Vitiello, Benedetto; Ramadan, Yaser; Witwer, Andrea; Lindsay, Ronald; Swiezy, Naomi; Kohn, Arlene; Cronin, Pegeen; McGough, James; Lee, Lisa Sea Yun; Martin, Andres; Koenig, Kathleen; Carroll, Deirdre; Lancor, Allison; Gonzalez, Nilda M.; Grados, Marco; Chuang, Shirley; Davies, Mark; Robinson, James; McMahon, Don.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 5, 10.2006, p. 589-598.

Research output: Contribution to journalArticle

Scahill, L, Aman, MG, McDougle, CJ, McCracken, JT, Tierney, E, Dziura, J, Arnold, LE, Posey, D, Young, C, Shah, B, Ghuman, J, Ritz, L, Vitiello, B, Ramadan, Y, Witwer, A, Lindsay, R, Swiezy, N, Kohn, A, Cronin, P, McGough, J, Lee, LSY, Martin, A, Koenig, K, Carroll, D, Lancor, A, Gonzalez, NM, Grados, M, Chuang, S, Davies, M, Robinson, J & McMahon, D 2006, 'A prospective open trial of guanfacine in children with pervasive developmental disorders', Journal of Child and Adolescent Psychopharmacology, vol. 16, no. 5, pp. 589-598. https://doi.org/10.1089/cap.2006.16.589
Scahill, Lawrence ; Aman, Michael G. ; McDougle, Christopher J. ; McCracken, James T. ; Tierney, Elaine ; Dziura, James ; Arnold, L. Eugene ; Posey, David ; Young, Christopher ; Shah, Bhavik ; Ghuman, Jaswinder ; Ritz, Louise ; Vitiello, Benedetto ; Ramadan, Yaser ; Witwer, Andrea ; Lindsay, Ronald ; Swiezy, Naomi ; Kohn, Arlene ; Cronin, Pegeen ; McGough, James ; Lee, Lisa Sea Yun ; Martin, Andres ; Koenig, Kathleen ; Carroll, Deirdre ; Lancor, Allison ; Gonzalez, Nilda M. ; Grados, Marco ; Chuang, Shirley ; Davies, Mark ; Robinson, James ; McMahon, Don. / A prospective open trial of guanfacine in children with pervasive developmental disorders. In: Journal of Child and Adolescent Psychopharmacology. 2006 ; Vol. 16, No. 5. pp. 589-598.
@article{e47eda330cb04cb8b0a7a440d7f8899a,
title = "A prospective open trial of guanfacine in children with pervasive developmental disorders",
abstract = "Objective: A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity. The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in children with FDD and hyperactivity. Methods: Children with PDD accompanied by hyperactivity entered the open-label trial if there was a recent history of failed treatment with methylphenidate or the child did not improve on methylphenidate in a multisite, placebo-controlled trial. Results: Children (23 boys and 2 girls) with a mean age of 9.03 (±3.14) years entered the open-label trial. After 8 weeks of treatment, the parent-rated Hyperactivity subscale of the Aberrant Behavior Checklist (ABC) went from a mean of 31.3 (±8.89) at baseline to 18.9 (±10.37) (effect size = 1.4; p < 0.001). The teacher-rated Hyperactivity subscale decreased from a mean of 29.9 (±9.12) at baseline to 22.3 (±9.44)-(effect size = 0.83; p < 0.01). Twelve children (48{\%}) were rated as Much Improved or Very Much Improved on the Clinical Global Impressions-Improvement. Doses ranged from 1.0 to 3.0 mg/day in two or three divided doses. Common adverse effects included irritability, sedation, sleep disturbance (insomnia or midsleep awakening), and constipation. Irritability led to discontinuation in 3 subjects. There were no significant changes in pulse, blood pressure, or electrocardiogram. Conclusions: Guanfacine may be useful for the treatment of hyperactivity in children with PDD. Placebo-controlled studies are needed to guide clinical practice.",
author = "Lawrence Scahill and Aman, {Michael G.} and McDougle, {Christopher J.} and McCracken, {James T.} and Elaine Tierney and James Dziura and Arnold, {L. Eugene} and David Posey and Christopher Young and Bhavik Shah and Jaswinder Ghuman and Louise Ritz and Benedetto Vitiello and Yaser Ramadan and Andrea Witwer and Ronald Lindsay and Naomi Swiezy and Arlene Kohn and Pegeen Cronin and James McGough and Lee, {Lisa Sea Yun} and Andres Martin and Kathleen Koenig and Deirdre Carroll and Allison Lancor and Gonzalez, {Nilda M.} and Marco Grados and Shirley Chuang and Mark Davies and James Robinson and Don McMahon",
year = "2006",
month = "10",
doi = "10.1089/cap.2006.16.589",
language = "English",
volume = "16",
pages = "589--598",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - A prospective open trial of guanfacine in children with pervasive developmental disorders

AU - Scahill, Lawrence

AU - Aman, Michael G.

AU - McDougle, Christopher J.

AU - McCracken, James T.

AU - Tierney, Elaine

AU - Dziura, James

AU - Arnold, L. Eugene

AU - Posey, David

AU - Young, Christopher

AU - Shah, Bhavik

AU - Ghuman, Jaswinder

AU - Ritz, Louise

AU - Vitiello, Benedetto

AU - Ramadan, Yaser

AU - Witwer, Andrea

AU - Lindsay, Ronald

AU - Swiezy, Naomi

AU - Kohn, Arlene

AU - Cronin, Pegeen

AU - McGough, James

AU - Lee, Lisa Sea Yun

AU - Martin, Andres

AU - Koenig, Kathleen

AU - Carroll, Deirdre

AU - Lancor, Allison

AU - Gonzalez, Nilda M.

AU - Grados, Marco

AU - Chuang, Shirley

AU - Davies, Mark

AU - Robinson, James

AU - McMahon, Don

PY - 2006/10

Y1 - 2006/10

N2 - Objective: A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity. The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in children with FDD and hyperactivity. Methods: Children with PDD accompanied by hyperactivity entered the open-label trial if there was a recent history of failed treatment with methylphenidate or the child did not improve on methylphenidate in a multisite, placebo-controlled trial. Results: Children (23 boys and 2 girls) with a mean age of 9.03 (±3.14) years entered the open-label trial. After 8 weeks of treatment, the parent-rated Hyperactivity subscale of the Aberrant Behavior Checklist (ABC) went from a mean of 31.3 (±8.89) at baseline to 18.9 (±10.37) (effect size = 1.4; p < 0.001). The teacher-rated Hyperactivity subscale decreased from a mean of 29.9 (±9.12) at baseline to 22.3 (±9.44)-(effect size = 0.83; p < 0.01). Twelve children (48%) were rated as Much Improved or Very Much Improved on the Clinical Global Impressions-Improvement. Doses ranged from 1.0 to 3.0 mg/day in two or three divided doses. Common adverse effects included irritability, sedation, sleep disturbance (insomnia or midsleep awakening), and constipation. Irritability led to discontinuation in 3 subjects. There were no significant changes in pulse, blood pressure, or electrocardiogram. Conclusions: Guanfacine may be useful for the treatment of hyperactivity in children with PDD. Placebo-controlled studies are needed to guide clinical practice.

AB - Objective: A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity. The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in children with FDD and hyperactivity. Methods: Children with PDD accompanied by hyperactivity entered the open-label trial if there was a recent history of failed treatment with methylphenidate or the child did not improve on methylphenidate in a multisite, placebo-controlled trial. Results: Children (23 boys and 2 girls) with a mean age of 9.03 (±3.14) years entered the open-label trial. After 8 weeks of treatment, the parent-rated Hyperactivity subscale of the Aberrant Behavior Checklist (ABC) went from a mean of 31.3 (±8.89) at baseline to 18.9 (±10.37) (effect size = 1.4; p < 0.001). The teacher-rated Hyperactivity subscale decreased from a mean of 29.9 (±9.12) at baseline to 22.3 (±9.44)-(effect size = 0.83; p < 0.01). Twelve children (48%) were rated as Much Improved or Very Much Improved on the Clinical Global Impressions-Improvement. Doses ranged from 1.0 to 3.0 mg/day in two or three divided doses. Common adverse effects included irritability, sedation, sleep disturbance (insomnia or midsleep awakening), and constipation. Irritability led to discontinuation in 3 subjects. There were no significant changes in pulse, blood pressure, or electrocardiogram. Conclusions: Guanfacine may be useful for the treatment of hyperactivity in children with PDD. Placebo-controlled studies are needed to guide clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=33750966156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750966156&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.589

DO - 10.1089/cap.2006.16.589

M3 - Article

C2 - 17069547

AN - SCOPUS:33750966156

VL - 16

SP - 589

EP - 598

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 5

ER -